The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAGM.L Regulatory News (AGM)

  • There is currently no data for AGM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on Strategic Review & Other Matters

13 Jan 2023 07:00

RNS Number : 5953M
Applied Graphene Materials PLC
13 January 2023
 

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

13 January 2023

Applied Graphene Materials plc

("Applied Graphene Materials", the "Company" or the "Group")

Update on strategic review and other matters

The Board provides the following update in relation to the ongoing strategic review and other matters.

Strategic Review

The Company, in conjunction with Alvarez & Marsal Europe LLP as financial adviser, is continuing its discussions with various parties that have submitted non-binding indicative proposals for either the sale of the Group's trade and assets or of the shares in the Company's main operating subsidiary.

The Board had initially sought non-binding indicative proposals from interested parties with a view to completing a transaction by 31 January 2023. Completing a transaction on a solvent basis will, in all likelihood, require shareholder approval in a general meeting, as well as other regulatory approvals. Discussions with interested parties are ongoing and the Board is seeking to select a preferred party with whom to enter into legally binding contractual terms by 31 January 2023. The completion of any transaction will only take effect once those shareholder and regulatory approvals have been obtained and this will not take place before 31 January 2023.

The Board has also previously notified that 31 January 2023 would be the date on which the Group's working capital position is expected to become fully depleted. The Board has reviewed the Group's projected cash flows further and taken mitigating action where appropriate to reduce costs and maintain liquidity beyond 31 January 2023.

The Board now believes that, without any further funding (including, for example, any interim funding that, in all likelihood, will be required to progress a transaction with a preferred party to completion), the Company's available working capital will become fully depleted by 28 February 2023. 

As previously disclosed, the Board continues to take action to seek to protect the financial position of the Company, its shareholders and creditors in the event that the strategic review does not achieve a satisfactory result. In parallel with the strategic review, the process of statutory redundancy consultations with the Group's employees announced on 23 November 2022 is ongoing.

Current discussions with interested parties may be altered or terminated at any time and, accordingly, there can be no certainty that any final proposals will be made, nor as to the terms on which any such final proposals may be made. 

Annual Report and Accounts for the year ended 31 July 2022

The Board continues to work with its auditors, RSM UK Audit LLP, with a view to publishing the Company's annual report and accounts for the year ended 31 July 2022 ("FY22") by 31 January 2023, being the deadline for publication stipulated under the AIM Rules for Companies.

If the FY22 annual report and accounts are not published by the deadline, the Company's ordinary shares of two pence each ("Ordinary Shares") will be suspended from trading on AIM with effect from 1 February 2023 pending publication of the Company's FY22 annual report and accounts.

OTCQX Best Market US listing

The Ordinary Shares have, since 29 July 2021, also traded on the OTCQX Best Market in the United States. In order to reduce costs and continue to provide a facility for US-based shareholders to freely trade the Ordinary Shares, the Company has elected for its Ordinary Shares to be traded on the OTCQB Venture Market under the ticker symbol APGMF with effect from 17 January 2023.

The Board will continue to provide further updates as appropriate.

For further information, please contact:

Applied Graphene Materials  +44 (0) 1642 438 214

Adrian Potts, Chief Executive Officer

David Blain, Chief Financial Officer

Alvarez & Marsal Europe LLP +44 (0) 784 107 2042

Alex Baird abaird@alvarezandmarsal.com

Singer Capital Markets  (Nominated Adviser and Joint Broker) +44 (0) 207 496 3000

Peter Steel / Oliver Platts

Allenby Capital Limited (Joint Broker) +44 (0) 203 328 5656

Nick Athanas / Dan Dearden-Williams (Corporate Finance)

Hudson Sandler  +44 (0) 207 796 4133

Nick Lyon / Emily Dillon

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDGPUWWGUPWGMP
Date   Source Headline
25th Apr 20187:00 amRNSIssue of share options to Directors
18th Apr 20188:41 amRNSHolding(s) in Company
10th Apr 20187:00 amRNSInterim Results
8th Mar 20187:00 amRNSCollaboration with SHD and Magna Exteriors
1st Feb 20187:00 amRNSBoard Change
15th Jan 20189:22 amRNSHolding(s) in Company
10th Jan 20185:30 pmRNSHolding(s) in Company
10th Jan 20184:40 pmRNSSecond Price Monitoring Extn
10th Jan 20184:35 pmRNSPrice Monitoring Extension
8th Jan 20181:21 pmRNSHolding(s) in Company
4th Jan 20187:00 amRNSResult of AGM
3rd Jan 20187:00 amRNSAGM Statement
12th Dec 20177:00 amRNSNotice of AGM
7th Nov 20179:47 amRNSHolding(s) in Company
2nd Nov 20177:00 amRNSDirector/PDMR Shareholding
30th Oct 20171:15 pmRNSResults of Open Offer and General Meeting
12th Oct 20175:19 pmRNSPosting of Circular and Notice of General Meeting
10th Oct 20176:16 pmRNSFurther Details on the Fundraising
10th Oct 201711:41 amRNSClose of Accelerated Bookbuild
10th Oct 201711:00 amRNSPrice Monitoring Extension
10th Oct 20177:05 amRNSProposed Placing by Accelerated Bookbuild
10th Oct 20177:00 amRNSPreliminary Results
22nd Aug 20177:00 amRNSInvestor Site Visit
24th May 20177:00 amRNSNew Graphene Delivery Technology & Trading Update
22nd May 20174:18 pmRNSIssue of Equity and Total Voting Rights
26th Apr 20174:35 pmRNSPrice Monitoring Extension
11th Apr 20177:00 amRNSInterim Results
7th Apr 20174:40 pmRNSSecond Price Monitoring Extn
7th Apr 20174:35 pmRNSPrice Monitoring Extension
5th Apr 20174:40 pmRNSSecond Price Monitoring Extn
5th Apr 20174:35 pmRNSPrice Monitoring Extension
1st Feb 20177:00 amRNSGrant of Options
30th Jan 20177:00 amRNSShare Purchase by CFO-Designate
25th Jan 20177:00 amRNSBoard & Operational Appointments
20th Dec 20167:00 amRNSAGM Statement
31st Oct 20167:01 amRNSDirector/PDMR Shareholding
31st Oct 20167:00 amRNSDirectorate Change
17th Oct 20167:00 amRNSFinal Results
14th Oct 20167:00 amRNSFirst Production Order
12th Aug 20167:38 amRNSExercise of Share Options and PDMR Dealing
12th Aug 20167:00 amRNSDirectorate Change
12th Aug 20167:00 amRNSPeriod end trading update and notice of results
8th Aug 20167:00 amRNSProduct Development and New JDA
23rd Mar 20167:00 amRNSInterim Results
26th Jan 20163:21 pmRNSHolding(s) in Company
26th Jan 201612:15 pmRNSResult of AGM
25th Jan 20167:00 amRNSAGM Statement
22nd Jan 201610:33 amRNSHolding(s) in Company
13th Jan 20169:08 amRNSHolding(s) in Company
11th Jan 20163:42 pmRNSIssue of share options to Directors

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.